BR112022000494A2 - Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica - Google Patents
Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêuticaInfo
- Publication number
- BR112022000494A2 BR112022000494A2 BR112022000494A BR112022000494A BR112022000494A2 BR 112022000494 A2 BR112022000494 A2 BR 112022000494A2 BR 112022000494 A BR112022000494 A BR 112022000494A BR 112022000494 A BR112022000494 A BR 112022000494A BR 112022000494 A2 BR112022000494 A2 BR 112022000494A2
- Authority
- BR
- Brazil
- Prior art keywords
- polymorph
- treating
- disease
- methods
- inhibiting
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000002235 sarcomere Anatomy 0.000 title abstract 2
- IOVAZWDIRCRMTM-OAHLLOKOSA-N N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide Chemical compound C(C)C1=NC(=NO1)C=1C=C2CC[C@H](C2=CC=1)NC(=O)C=1C=NN(C=1)C IOVAZWDIRCRMTM-OAHLLOKOSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875350P | 2019-07-17 | 2019-07-17 | |
| PCT/US2020/042387 WO2021011807A1 (en) | 2019-07-17 | 2020-07-16 | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000494A2 true BR112022000494A2 (pt) | 2022-03-03 |
Family
ID=71995103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000494A BR112022000494A2 (pt) | 2019-07-17 | 2020-07-16 | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220315571A1 (https=) |
| EP (2) | EP3999180B1 (https=) |
| JP (2) | JP7624431B2 (https=) |
| KR (1) | KR20220084008A (https=) |
| CN (3) | CN114555590B (https=) |
| AU (1) | AU2020313965A1 (https=) |
| BR (1) | BR112022000494A2 (https=) |
| CA (1) | CA3144975A1 (https=) |
| CL (1) | CL2022000054A1 (https=) |
| DK (1) | DK3999180T3 (https=) |
| ES (1) | ES2980885T3 (https=) |
| FI (1) | FI3999180T3 (https=) |
| HR (1) | HRP20240713T1 (https=) |
| HU (1) | HUE066891T2 (https=) |
| IL (1) | IL289875A (https=) |
| LT (1) | LT3999180T (https=) |
| MX (1) | MX2022000504A (https=) |
| PH (1) | PH12022550123A1 (https=) |
| PL (1) | PL3999180T3 (https=) |
| PT (1) | PT3999180T (https=) |
| RS (1) | RS65611B1 (https=) |
| SI (1) | SI3999180T1 (https=) |
| SM (1) | SMT202400224T1 (https=) |
| TW (1) | TWI865562B (https=) |
| WO (1) | WO2021011807A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| MX2024001294A (es) | 2021-08-03 | 2024-02-13 | Cytokinetics Inc | Proceso para la preparacion de aficamten. |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| EP4565230A1 (en) | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| US20250295639A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| MX2024001294A (es) * | 2021-08-03 | 2024-02-13 | Cytokinetics Inc | Proceso para la preparacion de aficamten. |
-
2020
- 2020-07-16 EP EP20753562.6A patent/EP3999180B1/en active Active
- 2020-07-16 CN CN202080059660.0A patent/CN114555590B/zh active Active
- 2020-07-16 DK DK20753562.6T patent/DK3999180T3/da active
- 2020-07-16 CN CN202411172321.XA patent/CN119119018A/zh active Pending
- 2020-07-16 ES ES20753562T patent/ES2980885T3/es active Active
- 2020-07-16 PT PT207535626T patent/PT3999180T/pt unknown
- 2020-07-16 RS RS20240598A patent/RS65611B1/sr unknown
- 2020-07-16 MX MX2022000504A patent/MX2022000504A/es unknown
- 2020-07-16 SM SM20240224T patent/SMT202400224T1/it unknown
- 2020-07-16 PL PL20753562.6T patent/PL3999180T3/pl unknown
- 2020-07-16 LT LTEPPCT/US2020/042387T patent/LT3999180T/lt unknown
- 2020-07-16 SI SI202030443T patent/SI3999180T1/sl unknown
- 2020-07-16 PH PH1/2022/550123A patent/PH12022550123A1/en unknown
- 2020-07-16 WO PCT/US2020/042387 patent/WO2021011807A1/en not_active Ceased
- 2020-07-16 CA CA3144975A patent/CA3144975A1/en active Pending
- 2020-07-16 HR HRP20240713TT patent/HRP20240713T1/hr unknown
- 2020-07-16 US US17/627,599 patent/US20220315571A1/en active Pending
- 2020-07-16 EP EP24174636.1A patent/EP4487911A1/en active Pending
- 2020-07-16 KR KR1020227004639A patent/KR20220084008A/ko active Pending
- 2020-07-16 HU HUE20753562A patent/HUE066891T2/hu unknown
- 2020-07-16 BR BR112022000494A patent/BR112022000494A2/pt unknown
- 2020-07-16 JP JP2022502215A patent/JP7624431B2/ja active Active
- 2020-07-16 AU AU2020313965A patent/AU2020313965A1/en active Pending
- 2020-07-16 TW TW109124093A patent/TWI865562B/zh active
- 2020-07-16 CN CN202411172308.4A patent/CN118908951A/zh active Pending
- 2020-07-16 FI FIEP20753562.6T patent/FI3999180T3/fi active
-
2022
- 2022-01-10 CL CL2022000054A patent/CL2022000054A1/es unknown
- 2022-01-16 IL IL289875A patent/IL289875A/en unknown
-
2025
- 2025-01-20 JP JP2025007662A patent/JP7755090B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000494A2 (pt) | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica | |
| BR112022000523A2 (pt) | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica | |
| PH12022550083A1 (en) | Cardiac sarcomere inhibitor oral formulations | |
| PH12020551304A1 (en) | Novel crystalline forms | |
| BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
| IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
| BR112019009129A2 (pt) | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| MX2018001193A (es) | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| JOP20210039B1 (ar) | مركبات بيريدين 6،2 - ديامينو | |
| BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| PH12021553161A1 (en) | Disubstituted pyrazole compounds as ketohexokinase inhibitors. | |
| RU2017109355A (ru) | Гетероциклические соединения и их применение | |
| BR112021026531A2 (pt) | Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2 | |
| EA201892460A1 (ru) | Производные аденина как ингибиторы протеинкиназ | |
| CL2022000050A1 (es) | Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida | |
| CR20200619A (es) | Compuestos de cianotriazol y usos de los mismos | |
| EA201892687A1 (ru) | Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение | |
| BR112022001184A2 (pt) | Composto da fórmula (i), composição farmacêutica, método de tratamento de uma doença mediada por cx3cr1 e método de modulação de cx3cr1 | |
| HK40074727A (en) | Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide | |
| HK40075684B (en) | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide | |
| RU2018120308A (ru) | Производное аминоазола | |
| TH91426B (th) | ตู้เย็น | |
| TH167958A (th) | โมเลกุลสำหรับการให้กับเซลล์มะเร็งที่ ros1 กลายพันธุ์ | |
| RU2020127993A (ru) | Терапевтическое средство для лечения гепатоцеллюлярной карциномы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |